{"product_id":"bmy-bcg-matrix","title":"(BMY) Bristol-Myers Squibb Company BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Bristol-Myers Squibb Company BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio planning. The page already shows a real preview of the analysis, so you can review the actual format and content before purchase. Buy the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEliquis, No. 1 revenue brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEliquis remains Bristol-Myers Squibb Company’s No. 1 revenue brand and a global DOAC leader. It delivered $13.3 billion in 2024 sales and kept broad share in atrial fibrillation and VTE prevention, with demand still rising across major markets in 2025. That scale makes it a clear Star: high growth, high share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpdivo, PD-1 oncology leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOpdivo is Bristol-Myers Squibb Company’s core PD-1 asset and a clear Star in the BCG Matrix, with broad use across more than 10 cancer types and 50-plus line-extensions and combo settings. It still anchors the immuno-oncology franchise, with 2024 net sales of about $9.0 billion and steady demand in lung, renal, and melanoma care. New regimens with Yervoy and chemo keep it in growth mode, not maturity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReblozyl, anemia growth brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReblozyl is a Stars in Bristol-Myers Squibb Company’s BCG matrix: it is approved for anemia in MDS and beta thalassemia, and 2025 sales have kept climbing, with 2024 revenue above $1.2 billion. Demand is rising as hematology use broadens, and the drug’s niche leadership supports strong pricing and volume growth. That mix of label breadth and fast uptake makes it a clear growth engine for Bristol-Myers Squibb Company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBreyanzi, CAR-T scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBreyanzi is BMS’s CAR-T growth star for large B-cell lymphoma and other B-cell cancers. U.S. use widened after its 2024 second-line LBCL approval, and BMS said 2025 demand is rising as more centers adopt CAR-T and referral delays ease. The CAR-T field still has only a few approved rivals, so scale-up can keep driving sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader label, bigger patient pool\u003c\/li\u003e\n\u003cli\u003ePhysician uptake is still rising\u003c\/li\u003e\n\u003cli\u003eCAR-T remains a fast-growth niche\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat makes Breyanzi a clear Star in BMS’s BCG mix: high market growth and strong share gain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCamzyos, first-in-class HCM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCamzyos, launched in 2022 for obstructive hypertrophic cardiomyopathy (oHCM), has become one of Bristol-Myers Squibb Company’s fastest-growing newer brands, with 2024 sales at about $1.0 billion. The addressable market is still widening as diagnosis and treatment rates rise, which supports Star status in the BCG matrix. \u003c\/p\u003e\n\u003cp\u003eThat growth is tied to a large untreated pool: oHCM affects about 1 in 500 people, and BMS says Camzyos remains early in its launch curve. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2022 launch in oHCM\u003c\/li\u003e\n\u003cli\u003e~$1.0B 2024 sales\u003c\/li\u003e\n\u003cli\u003eFast-growing BMS brand\u003c\/li\u003e\n\u003cli\u003eMarket still expanding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBristol-Myers’ Star Brands Keep Growing: Eliquis, Opdivo, and Beyond\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s Stars are Eliquis, Opdivo, Reblozyl, Breyanzi, and Camzyos. They combine strong share with still-growing demand, led by Eliquis at $13.3B and Opdivo at about $9.0B in 2024, while Reblozyl, Breyanzi, and Camzyos kept scaling in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eStar signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEliquis\u003c\/td\u003e\n\u003ctd\u003eTop DOAC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpdivo\u003c\/td\u003e\n\u003ctd\u003eIO scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCamzyos\u003c\/td\u003e\n\u003ctd\u003eFast launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBristol-Myers Squibb’s BCG Matrix maps its drugs by growth and share to spot Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBristol-Myers Squibb BCG Matrix: one-page quadrant view to spot wins, cuts, and cash cows fast\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clean source trail for Bristol-Myers Squibb, making claims easier to verify and decisions easier to defend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevlimid, legacy myeloma cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevlimid was still a cash generator for Bristol-Myers Squibb Company, with 2024 net sales of about $4.4 billion even as generic erosion deepened. The drug’s long-running multiple myeloma demand keeps it relevant, but growth is now limited and the profile is clearly mature. In BCG terms, it fits a Cash Cow: low growth, steady cash, shrinking but still meaningful contribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrencia, mature RA biologic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrencia remains a mature BMS immunology cash cow, with 2025 sales of about $2.8 billion across rheumatoid and psoriatic arthritis. The brand keeps a loyal prescriber base and still delivers useful margin, even as growth stays low. Its long market history and steady refill demand help offset slow volume pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePomalyst\/Imnovid, established myeloma franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePomalyst\/Imnovid is a mature oral myeloma therapy with a clear clinical role in relapsed and refractory disease, so it still brings steady cash flow for Bristol Myers Squibb Company. The brand is long established and has outlasted many newer oncology launches. Growth is limited because the market is crowded and newer combo regimens are taking share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eYervoy, stable IO combo brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eYervoy is a mature CTLA-4 checkpoint inhibitor and still a core cash cow for Bristol-Myers Squibb Company because it is used mainly in combination regimens, not as a growth driver. In recent company reporting, Yervoy generated about $2.3 billion in annual sales, showing durable demand in melanoma and other tumors even as the brand is past peak growth. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUsed mainly in combo regimens\u003c\/li\u003e\n\u003cli\u003eDurable melanoma role\u003c\/li\u003e\n\u003cli\u003eAbout $2.3B annual sales\u003c\/li\u003e\n\u003cli\u003eMature, cash-generative brand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIts value in the BCG Matrix comes from steady cash flow, strong clinical positioning, and limited need for heavy new launch spending. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSprycel, residual CML cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSprycel is Bristol-Myers Squibb Company’s legacy CML cash cow: a long-running branded leukemia drug that still throws off cash, but growth has faded under patent expiry and generic pressure. Its sales are now more about harvesting residual demand than expanding share.\u003c\/p\u003e\n\u003cp\u003eIn the BCG view, Sprycel fits a mature, low-growth, high-cash role, with the remaining revenue stream tied to the brand’s installed base and late-stage line use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegacy CML brand\u003c\/li\u003e\n\u003cli\u003eWeak growth, heavy generic pressure\u003c\/li\u003e\n\u003cli\u003eResidual sales support cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBristol-Myers’ Cash Cows Keep the Profits Flowing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s Cash Cows are mature brands that still throw off strong cash despite low growth. Revlimid, Orencia, Pomalyst\/Imnovid, Yervoy, and Sprycel all fit this role, with Orencia at about $2.8 billion in 2025 sales and Yervoy at about $2.3 billion annual sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2025 Sales\u003c\/th\u003e\n\u003cth\u003eBCG Role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrencia\u003c\/td\u003e\n\u003ctd\u003e$2.8B\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYervoy\u003c\/td\u003e\n\u003ctd\u003e$2.3B\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eBristol-Myers Squibb Company Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Bristol-Myers Squibb Company BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No watermarks, no demo pages—just the full, professionally formatted report ready for immediate use. Once purchased, your file is instantly available for download, editing, or presentation. What you preview is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbraxane, genericized chemo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbraxane, a protein-bound paclitaxel launched in 2005, is now a mature legacy oncology product for Bristol-Myers Squibb Company. Generic versions have driven sharp price and volume erosion, so growth is weak and the asset is in decline rather than expansion. In a BCG Matrix, it fits Dogs: low growth, heavy competitive pressure, and limited cash-generation upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmpliciti, limited-share myeloma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmpliciti stays a narrow-share myeloma antibody, with 2025 sales still under $200 million and far below Bristol-Myers Squibb Company’s top brands. In a crowded market led by larger regimens, it has not built a major franchise, so growth stays weak. That makes it a clear BCG Dog: subscale, low momentum, and limited strategic weight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInrebic, niche myelofibrosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInrebic is Bristol-Myers Squibb Company's oral JAK2 inhibitor for adult myelofibrosis, but the market is small and crowded. Myelofibrosis affects only about 1.5 people per 100,000 each year, so commercial scale stays limited. That fits a Dogs label in the BCG Matrix: low growth, narrow reach, and tough competition from better-known JAK inhibitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOnureg, small AML uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOnureg, the oral azacitidine used for AML maintenance, stayed a small BMS brand in FY2025, with sales still well below the company’s top oncology assets. Its uptake remained modest, so the product has limited growth and limited scale in the BCG matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAML maintenance use is niche.\u003c\/li\u003e\n\u003cli\u003eFY2025 sales stayed modest.\u003c\/li\u003e\n\u003cli\u003eScale lags key oncology brands.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eZeposia, subscale immunology asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZeposia is used in relapsing forms of multiple sclerosis and ulcerative colitis, but it stays a subscale asset in Bristol Myers Squibb Company’s immunology set. The addressable market is large, yet Zeposia still contributes only a small slice of Bristol Myers Squibb Company’s revenue, so it is not a core growth engine. In BCG terms, it fits more like a \"question mark\" than a \"star\".\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge market, small Bristol Myers Squibb Company share\u003c\/li\u003e\n\u003cli\u003eUsed in MS and GI disease\u003c\/li\u003e\n\u003cli\u003eGrowth still below top-tier assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBristol-Myers’ Dogs: Small, Shrinking, and Under Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAbraxane, Empliciti, Inrebic, and Onureg sit in Bristol-Myers Squibb Company’s Dogs: FY2025 sales were small or declining, with weak growth, niche demand, and heavy competition. Zeposia is still subscale, so it is not a core BCG star.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eFY2025 sales\u003c\/th\u003e\n\u003cth\u003eBCG\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbraxane\u003c\/td\u003e\n\u003ctd\u003eDeclining\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmpliciti\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;$200M\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInrebic\u003c\/td\u003e\n\u003ctd\u003eSmall\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSotyktu, psoriasis launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSotyktu was approved in 2022 for moderate-to-severe plaque psoriasis, a market with millions of patients worldwide and about 2% to 3% global prevalence. Bristol-Myers Squibb Company is starting from a low base, so the brand needs fast share gains to move from Question Mark to Star. In BCG terms, that means rapid uptake, strong persistence, and clear differentiation versus entrenched dermatology brands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCobenfy, schizophrenia launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCobenfy, launched in 2024 for schizophrenia, is still an early bet for Bristol-Myers Squibb Company in a large CNS space. Schizophrenia affects about 24 million people worldwide, but Cobenfy still needs to win share against entrenched antipsychotics, so its 2025 uptake is still uncertain. That makes it a classic question mark with high upside and high execution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpdualag, melanoma combo launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOpdualag, Bristol-Myers Squibb Company’s fixed-dose nivolumab and relatlimab combo for advanced melanoma, fits the Question Mark bucket: the market is growing, but share is still being built. In RELATIVITY-047, median progression-free survival was 10.1 months versus 4.6 months for nivolumab alone, supporting adoption. Upside stays tied to faster uptake and broader use in first-line advanced melanoma.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAbecma, BCMA CAR-T\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAbecma is Bristol-Myers Squibb Company’s BCMA CAR-T for relapsed or refractory multiple myeloma, a fast-growing cell-therapy niche. The category is expanding, but Abecma is still battling for share against Carvykti, so it fits BCG’s question mark: high growth, weak relative position.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBCMA CAR-T targets multiple myeloma\u003c\/li\u003e\n\u003cli\u003eHigh-growth cell-therapy market\u003c\/li\u003e\n\u003cli\u003eShare battle keeps it a question mark\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCamzyos expansion, broader cardiology use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCamzyos is still a Question Mark in Bristol Myers Squibb Company’s BCG mix: the HCM market is growing, but it is not fully penetrated yet. The company is pushing diagnosis expansion and doctor education, so volume can still scale fast. \u003c\/p\u003e\n\u003cp\u003eMarket potential is high, but share is still being won case by case. That keeps Camzyos attractive, but it also means Bristol Myers Squibb Company must keep spending on awareness and echo-based diagnosis. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUnderdiagnosed HCM still limits uptake\u003c\/li\u003e\n\u003cli\u003eEducation drives new patient starts\u003c\/li\u003e\n\u003cli\u003eShare growth remains the key test\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e5 BMS question marks with big markets but still weak share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSotyktu, Cobenfy, Opdualag, Abecma, and Camzyos are Bristol-Myers Squibb Company question marks because they sit in large or growing markets but still need stronger share. Cobenfy targets schizophrenia, a market of about 24 million people worldwide, while Opdualag showed 10.1-month median PFS in RELATIVITY-047 versus 4.6 months for nivolumab alone. Camzyos and Abecma still depend on faster uptake and broader use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCobenfy\u003c\/td\u003e\n\u003ctd\u003eEarly share build\u003c\/td\u003e\n\u003ctd\u003e24M schizophrenia cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpdualag\u003c\/td\u003e\n\u003ctd\u003eClinical edge\u003c\/td\u003e\n\u003ctd\u003e10.1 vs 4.6 months PFS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191786709257,"sku":"bmy-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bmy-bcg-matrix.webp?v=1783678444","url":"https:\/\/dcfanalyst.com\/products\/bmy-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}